POSTDOCTORAL RESEARCH TRAINING IN CANCER IMMUNOLOGY

癌症免疫学博士后研究培训

• 批准号: 7123850
• 负责人: HARVEY CANTOR
• 金额: $ 24.18万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-05 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7123850
• 关键词: POSTDOCTORAL; RESEARCH; TRAINING; CANCER; IMMUNOLOGY

DESCRIPTION (provided by applicant): The last several years have been a period of extraordinary scientific achievement and cancer research expansion, both at Dana-Farber Cancer Institute (DFCI) and within the Harvard Medical School community. Although significant progress has been made in the diagnosis and treatment of cancer, this disease continues to represent a major cause of childhood and adult mortality. Important advances in our fundamental understanding of the immune response have suggested new clinical approaches to the diagnosis and treatment of leukemias and solid tumors. Significant advances have occurred in the areas of basic biological science, including tumor suppressor genes, cell cycle regulation, oncogene signaling, cell differentiation, apoptosis control, organogenesis and angiogenesis. Recent advances in targeted cancer therapies, new modalities of cancer cell imaging, and a deeper understanding of genetics and cancer risk highlight the potential of these discoveries to translational research which, in turn, has opened new areas of opportunity for today's young scientists. An essential part of this effort is the training of young scientists in basic and clinical immunology to become independent investigators in cancer immunology. At DFCI, translational research has been an ongoing collaborative effort between faculty in basic and clinical Immunology for many years. Recent formation of the Dana-Farber/Harvard Cancer Center, a consortium of the affiliated hospitals, has allowed expansion of our training faculty to include distinguished scientists from the entire Harvard Medical School community, all of whom are leading investigators in basic and translational/clinical immunology. In addition, expanded infrastructure and core resources have enhanced access to reagents and provide a more efficient framework in which to carry out research. The program will continue to be directed by Dr. Harvey Cantor who, in conjunction with the Training Program Subcommittee, is responsible for candidate selection, program curriculum, annual review of trainee's research and fostering of interactions among student and faculty members within the Program. The long-range goal of the Program is to train basic scientists to conduct independent high-quality research in cancer immunology.

描述（由申请人提供）：最近几年是达纳 - 法伯癌症研究所（DFCI）和哈佛医学院社区内的非凡科学成就和癌症研究扩展的时期。 尽管在诊断和治疗癌症方面取得了重大进展，但该疾病继续代表了儿童和成人死亡率的主要原因。 我们对免疫反应的基本理解的重要进展提出了对白血病和实体瘤的诊断和治疗的新临床方法。 基本生物科学领域已经发生了重大进展，包括肿瘤抑制基因，细胞周期调节，癌基因信号传导，细胞分化，凋亡控制，器官发生和血管生成。 靶向癌症疗法的最新进展，癌细胞成像的新方式以及对遗传学和癌症风险的更深入的了解突出了这些发现对转化研究的潜力，这反过来又为当今的年轻科学家开辟了新的机会领域。 这项工作的重要组成部分是培训年轻科学家在基本和临床免疫学上成为癌症免疫学领域的独立研究者。 多年来，在DFCI，转化研究一直是基本和临床免疫学教师之间的持续合作努力。 近期医院联盟的Dana-Farber/Harvard Cancer Center的最新成立使我们的培训学院扩大了培训学院，其中包括整个哈佛医学院社区的杰出科学家，他们都是基本和转化/临床免疫学领先的研究人员。 此外，扩大的基础设施和核心资源增强了对试剂的访问，并提供了更有效的框架来进行研究。 该计划将继续由Harvey Cantor博士指导，Harvey Cantor博士与培训计划小组委员会一起负责候选人选择，计划课程，对学员的研究年度审查以及该计划中学生和教职员工之间的互动。 该计划的远程目标是培训基础科学家，从事癌症免疫学方面的独立高质量研究。